Mylan N.V. (NASDAQ:MYL) and Flexion Therapeutics, Inc. (NASDAQ:FLXN) are both Healthcare companies that recently hit new low. Naturally, this has created a bit of a stir amongst investors. We will compare the two companies across various metrics including growth, profitability, risk, return, dividends, and valuation to determine if one is a better choice than the other.Mylan N.V. (NASDAQ:MYL) operates in the Drugs – Generic segment of the Healthcare sector. The company has grown sales at a 12.60% annual rate over the past five years, putting it in the high growth category. MYL has a net profit margin of 7.30% and is more profitable than the average company in the Drugs – Generic industry. In terms of efficiency, MYL has an asset turnover ratio of 0.34. This figure represents the amount of revenue a company generates per dollar of assets. MYL’s financial leverage ratio is 1.69, which indicates that the company’s asset base is primarily funded by equity capital. Company’s return on equity, which is really just the product of the company’s profit margin, asset turnover, and financial leverage ratios, is 7.10%, which is worse than the Drugs – Generic industry average ROE.Stock’s free cash flow yield, which represents the amount of cash available to investors before dividends, expressed as a percentage of the stock price, is 2.55. Company trades at a P/E ratio of 22.51, and is less expensive than the average stock in the Drugs – Generic industry. The average investment recommendation for MYL, taken from a group of Wall Street Analysts, is 2.20, or a buy.Over the past three months, Mylan N.V. insiders have been net buyers, dumping a net of 0 shares. This implies that insiders have been feeling relatively bearish about the outlook for MYL. Insider activity and sentiment signals are important to monitor because they can shed light on how “risky” a stock is perceived to be at it’s current valuation. Knowing this, it makes sense to look at beta, a measure of market risk. MYL has a beta of 1.39 and therefore an above average level of market volatility.
     (adsbygoogle = window.adsbygoogle || []).push({});
Flexion Therapeutics, Inc. (NASDAQ:FLXN) operates in the Drugs – Generic segment of the Healthcare sector. FLXN’s return on equity of -60.30% is worse than the Drugs – Generic industry average.The average analyst recommendation for FLXN is 1.70, or a buy.Flexion Therapeutics, Inc. insiders have bought a net of 5,683 shares during the past three months, which implies that the company’s top executives have been feeling bullish about the stock’s outlook. Finally, FLXN’s beta of 1.05 indicates that the stock has an above average level of market risk.FLXN has the better fundamentals, scoring higher on leverage metrics.



(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});


Economy and Money Authors gives investors their free and unbiased view of Financial Markets and on what happening in Stock Market. Our team certainly analyze tons of Stocks every day and provide their fair opinion on them. We are always looking over financial statements, company’s earning, analyst upgrades/downgrades, joint ventures and balance sheets to keep our reader up to date.